Back to top

vaccines: Archive

Zacks Equity Research

FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab

The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.

PFENegative Net Change NVOPositive Net Change MRKPositive Net Change GLPGNegative Net Change

Zacks Equity Research

Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer

Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.

NVOPositive Net Change MRKPositive Net Change GLPGNegative Net Change OCUPNegative Net Change

Zacks Equity Research

FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma

Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.

MRKPositive Net Change MRNANegative Net Change GLPGNegative Net Change OCUPNegative Net Change

Zacks Equity Research

Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study

Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.

MRKPositive Net Change MRNANegative Net Change GLPGNegative Net Change OCUPNegative Net Change